Company intelligence / Profile preview

Burning Rock Biotech

Guangzhou, Guangdong, Chinair.brbiotech.com ↗

Ownership: Private
Development stage: Commercial

Overview

Burning Rock Biotech has commercialized multiple NGS-based diagnostic tests for tissue and liquid biopsy applications in oncology. Its products are used to guide individualized treatment decisions across a broad range of solid tumors. The company provides both central lab testing and companion diagnostic development services. It operates primarily in China but also has some presence internationally[2][3][4][5].

Therapeutic areas: Oncology
Modalities: NGS-based diagnosticsCompanion diagnostics
Industry: Molecular Diagnostics

Drug pipeline

1 asset

brigimadlin

Phase 2

Indications: MDM2-amplified TP53 wild-type solid tumors, Biliary Tract Carcinoma

Partnerships

Collaborates with hospitals and pharmaceutical companies for companion diagnostic development.

Beyond the preview

Go deeper on Burning Rock Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Burning Rock Biotech.

Explore the full profile